Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab dosing strategies in pediatric frequently relapsing or steroid-dependent nephrotic syndrome
ChiCTR2400094085Phase 4Not yet recruiting
- Sponsor
- Liuzhou Hospital of Guangzhou Women and Children's Medical Center
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in nephrosis (2 arms), sponsored by Liuzhou Hospital of Guangzhou Women and Children's Medical Center. Primary endpoint: 12-month sustained complete remission rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
nephrosis
Beyond the preview
Go deeper on ChiCTR2400094085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094085.